MentionFox
Home › funding signals › AN2 Therapeutics, Inc.
Form D · on the record

AN2 Therapeutics — $40M Form D filing, March 2026

AN2 Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-03-25.

AN2 Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on March 25, 2026. The filing reports $40M sold. Its industry group is Pharmaceuticals. It names Eric Easom (Executive Officer, Director), Joshua Eizen (Executive Officer), Lucy Day (Executive Officer) (SEC Form D, March 25, 2026).

Sell to companies like AN2 Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

88 companies raised this week, 1 had other signals.

Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.

fal - Features & Labels, Inc.$1BAI and software
fal - Features & Labels, Inc.$350MAI and software
SIERRA INTERNATIONAL NETWORK INC$300MAI and software
Zai Lab Ltd$250MBiotech
Databento Inc.$100MAI and software
Check one company free All companies that raised this week

5 more Pharmaceuticals raises in California within 90 days ↓

Is this your company?

Key facts

Run the free check on AN2 Therapeutics, Inc. →

AN2 Therapeutics, Inc.

New Form D on file · 2026-03-25 · the record

$40M
raise on the record
D
filing
16
investors in
CALIFORNIA
based
Open the record →

What the record says

FilingForm D
Filed2026-03-25
Industry groupPharmaceuticals
Entity typeCorporation
Incorporated inDELAWARE
BasedMENLO PARK, CALIFORNIA
CIK1880438
Accession0001880438-26-000001

Pitching, partnering or investing alongside them? See who really runs and owns AN2 Therapeutics, Inc.

Free to see. No signup.

Keep reading

More on the people and the money behind AN2 Therapeutics, Inc., from the filings we hold.

Raised through the same sales agent

Leerink Partners LLC received sales compensation on this raise and on 16 other raises we hold, nearest in date first:

More raises like this

Pharmaceuticals raises by companies based in California, filed within 90 days of this one, largest first.

What do you want to do with AN2 Therapeutics, Inc.?

Get the full cited report on AN2 Therapeutics, Inc.

What the filing shows about AN2 Therapeutics, Inc.

  • 16 investors had already put money in when it filed.
  • The filing names 12 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on AN2 Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Just raised? Your investors will ask for updates.

The weeks after a raise are when investors, other founders and press look AN2 Therapeutics, Inc. up. FoxPlug is your startup's chief of staff: it reads your whole stack and tells you what to fix, what to say and what to skip, for founders shipping with Claude Code, Codex or Cursor. It drafts your monthly investor update from your real numbers, and its free tools need no account. GetFoxChat puts an AI operator on AN2 Therapeutics, Inc.'s own site, named as you like, so the visitors this record sends you don't read one page and leave.

Who the filing names, and in what role

The filing gives AN2 Therapeutics, Inc.'s address as 1300 El Camino Real, Suite 100, Menlo Park, CA 94025.

What the filing says

  • Offered: $39,999,989. Sold: $39,999,989. Left to sell: nothing, all of it is sold. (filing)
  • Investors: 16 had already invested. (filing)
  • Date of first sale: March 10, 2026. (filing)
  • Types of securities: Equity; Options, warrants or other rights to acquire another security; Securities to be acquired on exercise of an option, warrant or other right. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on AN2 Therapeutics, Inc. See pricing

Is AN2 Therapeutics, Inc. a real, registered company?

AN2 Therapeutics, Inc. is a registered filer with the SEC (CIK 1880438) and has filed since 2026-03-25. 1 filing is on record, the latest on 2026-03-25.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs AN2 Therapeutics, Inc.?

AN2 Therapeutics, Inc.'s Form D of 2026-03-25 names Eric Easom, Joshua Eizen, Lucy Day and 9 more as its officers, directors or promoters.

How much has AN2 Therapeutics, Inc. raised?

Its new offerings report $40M sold across 1 offering, as its own filings state.

Pharmaceuticals · by week
This raise, $40M, filed week of Mar 23

Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $40M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on AN2 Therapeutics, Inc.?

What the filing shows about AN2 Therapeutics, Inc.

  • 16 investors had already put money in when it filed.
  • The filing names 12 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on AN2 Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on AN2 Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    2 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (an2therapeutics.com).

RSS

Tools for this story

Each opens in a new tab, filled in for AN2 Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

On these startup lists

Biotech startups

More on AN2 Therapeutics, Inc.

Share this page

Is this your company?

Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

AN2 Therapeutics, Inc.: Raised $40M, Form D filed 2026-03-25
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/an2-therapeutics-inc-form-d-26000001
Last updated 2026-10-20
Primary record: SEC filing 1 · SEC filing 2
AN2 Therapeutics raised $40M — SEC Form D filing, March 2026. MentionFox, 2026-10-20. https://mentionfox.com/funding/an2-therapeutics-inc-form-d-26000001